Production and characterization of polyclonal antibodies to human recombinant domain B-free antihemophilic factor VIII

Abstract

Moroctocog alpha is a human B-domain deleted recombinant factor VIII (BDDrFVIII), which represents a new generation of pure antihemophilic products. We describe here an optimized procedure for polyclonal anti-FVIII-antibody production with the use of BDDrFVIII as an immunogen. The main immunochemical characteristics of the produced antibodies and their potential biomedical applications are also reported. Rabbits were immunized with BDDrFVIII as an emulsion with Freund's adjuvant or with antigen immobilized in polyacrylamide gel (PAAG). Antibody titers in immune sera were assayed by enzyme-linked immunosorbent assay (ELISA). IgG purification was performed by affine chromatography on protein A-sepharose. Immune sera and IgG were tested by immunoblotting with the use of human plasma of healthy donors and people with hemophilia A, platelet lysates, and commercial plasma-derived concentrates as sources of FVIII-related antigens. FVIII-producing human umbilical vein cells were processed for immunocytochemical staining with the use of purified anti-FVIII-antibodies. Immunization of rabbits with PAAG-trapped antigen induced more potent immune response compared to the standard immunization procedure with Freund's adjuvant. The lowest working amount of immune IgG, measured by ELISA, was ~50 ng. Immunoblotting demonstrated that anti-BDDrFVIII antibodies effectively recognize the whole FVIII molecule (320 kDa), as well as different truncated polypeptides thereof, and are suitable for immunocytochemical analysis of FVIII-producing cells. An optimized procedure for the production of polyclonal antibodies against FVIII with the use of PAAG-immobilized BDDrFVIII (moroctocog alpha) was proposed and successfully validated. The produced antibodies are suitable for detecting and measuring FVIII-related antigens and may have various biomedical applications.

Identification of iron metabolism-related predictive markers of endometriosis and endometriosis-relevant ovarian cancer

“…Specific drugs can be used to treat hemophilia, scurvy, and other blood-related diseases, [ 66 – 68 ] and to treat and control episodes of bleeding as required. Regarding RRM2 , specific drugs can be used to treat melanoma, multiple myeloma, ovarian cancer, leukemia, non-Hodgkin lymphoma, and other diseases.…”

A polyclonal antibody against a recombinantly expressed Triticum aestivum RHT-D1A protein

“…The usual dose of a soluble protein administered with Freund’s adjuvant to rabbits is in the range of 50 to 1000 μg, and for mice, it is 10–200 μg; for goats or sheep, the typical dose is 250–5000 μg [ 28 ]. Nevertheless, for primary injection, most investigators use doses 100–200 μg [ 29 , 30 ] or even less than 25–50 μg [ 31 , 32 ]. It should be stressed that in some studies concerning the polyclonal antibody production in rabbits, for primary immunization, researchers have used doses of 400 to 500 μg [ 33 , 34 ] even up to 1.0 mg [ 35 , 36 ].…”

Big defensin from the scallop Argopecten purpuratus ApBD1 is an antimicrobial peptide which entraps bacteria through nanonets formation

“…The copyright holder for this preprint this version posted February 25, 2020. ; https://doi.org/10.1101/2020.02.25.965327 doi: bioRxiv preprint structure was thought to improve the obtention of specific antibodies as previously suggested (Tykhomyrov et al 2017).…”